<DOC>
	<DOCNO>NCT01921322</DOCNO>
	<brief_summary>This prospective , randomize ( open label ) , multi-center post-market study . The study compare effectiveness sensor-augmented pump ( SAP ) therapy versus multiple daily injection ( MDI ) therapy hospitalize patient insulin treat type 2 diabetes China</brief_summary>
	<brief_title>CEP270 China SAP Study</brief_title>
	<detailed_description>Primary objective : To compare length time achieve target glucose range use Self-Monitoring Blood Glucose ( SMBG ) , reference method , 722 Paradigm Real-Time insulin pump versus MDI Secondary Objectives : To compare glycemic variability ( use CGM reference method ) 722 Paradigm Real-Time insulin pump versus MDI This prospective , randomize ( open label ) , multi-center study . The clinical study staff conduct screening test accord inclusion/exclusion criterion order verify subject 's eligibility study . Inpatient Period A patient admit hospital treatment diabetes Randomization Subjects randomize ( 1:1 ratio ) group A B study database . A total 80 subject randomize 2 study group : - Group A wear 722 Paradigm Real-Time System ( treat 24h per day insulin infusion ) - Group B MDI wear CGMS-Gold ( treat 4 insulin injection ) . It anticipate total duration study within one year site initiation finalization data entry monitoring . Each subject participate study approximately 2 week .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Subject 18 65 year old time screen 2 . A clinical diagnosis type 2 diabetes &gt; 6 month prior screen determine Investigator , 3 . Treating insulin least one injection per day prior participate study 4 . Glycosylated hemoglobin ( A1C ) &gt; 8 % screen 5 . Subject need hospitalized receive treatment glucose management accord Endocrinologists ' discretion 6 . Subject willing follow protocol underdo study procedures 7 . Subject willing able provide inform write consent personally legal proxy 1 . Subject know hypersensitivity insulin insulin infusion set 2 . Subject treated drug know effect BG within 8 week enrollment diabetes medication insulin oral agent . 3. random blood glucose 33 mmol/L 4 . Subject currently use real time CGM therapy prior screen 5 . Subject currently use insulin pump therapy prior screen 6 . Female subject pregnant , plan become pregnant course study 7 . Patients critically ill must go intensive critical care unit per Investigator discretion 8 . Subject systemic disease medical condition find screen test may interfere safety patient efficacy study treatment , opinion Investigator , may preclude him/her participate study . The following include , limited , condition : Female subject positive serum pregnancy screen test Subject visually impair disability limit use RTCGM . Subject unresolved adverse skin condition area sensor placement device replacement ( e.g. , psoriasis , rash , Staphylococcus infection ) Subject disease know effect BG Active Graves ' disease Subject history alcohol abuse 9 . Any condition , may suitable study physician 's discretion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>